Edap Tms SA (EDAP) — 6-K Filings

6-K Filings (25)

• 6-K Filing — Nov 20, 2025
• EDAP TMS S.A. Files 6-K Report — Nov 18, 2025 Risk: low
  EDAP TMS S.A. filed a Form 6-K on November 18, 2025, to report its status as a foreign private issuer. The filing includes standard disclosures and signatures,
• 6-K Filing — Nov 6, 2025
• EDAP TMS S.A. Secures €36M EIB Credit Facility — Oct 20, 2025 Risk: low
  On October 17, 2025, EDAP TMS S.A. secured a €36.0 million credit facility agreement with the European Investment Bank (EIB). The company intends to utilize the
• EDAP TMS S.A. Files 6-K, Signals Strategic Shift — Sep 9, 2025 Risk: low
  EDAP TMS S.A. filed a Form 6-K on September 9, 2025, reporting as a foreign private issuer. The filing indicates the company is transitioning from legacy techno
• EDAP TMS SA Secures French Reimbursement for Prostate Cancer HIFU — Sep 8, 2025 Risk: low
  EDAP TMS S.A. announced on September 8, 2025, that its Focal One Robotic HIFU procedure for prostate cancer has received reimbursement under France's national u
• EDAP TMS SA: Strong Q2 HIFU Growth & Credit Facility LOI — Aug 28, 2025 Risk: medium
  EDAP TMS SA reported strong second quarter 2025 results, with a 140% year-over-year increase in Focal One® net placements and a 76.8% year-over-year increase in
• EDAP TMS SA Secures 36M Euro Credit Facility for Growth — Aug 26, 2025 Risk: medium
  EDAP TMS SA announced on August 26, 2025, a Letter of Intent for a 36 million Euro credit facility. This funding is intended to accelerate the company's growth
• EDAP TMS SA to Become U.S. Domestic Filer — Jul 1, 2025 Risk: low
  EDAP TMS SA announced on July 1, 2025, that it will transition from a Foreign Private Issuer to a U.S. Domestic Filer status, effective January 1, 2026. This ch
• EDAP TMS SA Files Form 6-K — Jun 2, 2025 Risk: low
  EDAP TMS S.A. filed a Form 6-K on June 2, 2025, reporting as a foreign private issuer. The filing indicates the company is subject to French regulations and pro
• EDAP TMS SA: Q1 2025 Results & CE Mark for Endometriosis — May 15, 2025 Risk: low
  EDAP TMS SA announced its first quarter 2025 financial results on May 15, 2025. The company achieved a record number of Focal One® Robotic HIFU System placement
• EDAP TMS SA Reports Record HIFU Revenue for 2024 — Mar 27, 2025 Risk: low
  EDAP TMS SA reported record High-Intensity Focused Ultrasound (HIFU) revenue for both the fourth quarter and full year of 2024. Full-year 2024 HIFU revenue reac
• EDAP TMS SA Appoints Glen French to Board of Directors — Mar 3, 2025 Risk: low
  EDAP TMS SA announced on March 3, 2025, the appointment of Glen French to its Board of Directors. Glen French brings extensive experience to the board of the gl
• EDAP TMS SA Reports Record Q4 Focal One Sales — Jan 13, 2025 Risk: low
  EDAP TMS SA announced preliminary record fourth quarter sales for its Focal One system, selling 11 units worldwide and achieving a record number of U.S. procedu
• EDAP TMS SA Appoints Joshua H. Levine to Board — Jan 10, 2025 Risk: low
  EDAP TMS SA announced on January 10, 2025, the appointment of Joshua H. Levine to its Board of Directors. Levine brings extensive experience in the medical devi
• EDAP TMS Focal One HIFU Shows Promise vs. Surgery — Dec 4, 2024 Risk: medium
  EDAP TMS S.A. announced on December 4, 2024, that the Landmark HIFI Study, the largest prospective, comparative, multi-center clinical study ever conducted with
• EDAP TMS SA Q3 Revenue Up 11.6%, HIFU Revenue Surges 48.2% — Nov 7, 2024 Risk: medium
  EDAP TMS SA reported third quarter 2024 financial results on November 7, 2024. The company announced worldwide revenue of EUR 13.1 million (USD 14.4 million), a
• EDAP TMS S.A. Reports Record Q2 2024 Revenue — Aug 28, 2024 Risk: low
  EDAP TMS S.A. reported record second quarter 2024 revenue of EUR 15.8 million (USD 17.0 million), a 10.6% increase compared to Q2 2023. For the first half of 20
• EDAP TMS SA: Robotic HIFU Shows Safety in Endometriosis Study — Jul 19, 2024 Risk: low
  EDAP TMS SA announced interim results from a Phase 3 study on July 19, 2024, evaluating its Robotic HIFU therapy for deep infiltrating endometriosis. The therap
• EDAP TMS SA Appoints Fran Schulz to Board of Directors — Jul 8, 2024 Risk: low
  EDAP TMS SA announced on July 8, 2024, the appointment of Fran Schulz to its Board of Directors. Schulz brings extensive experience to the company, which is a g
• EDAP TMS S.A. Reports Record Revenue in 2023 — Jun 7, 2024 Risk: low
  EDAP TMS S.A. reported a very productive and successful 2023, achieving record revenue and placing a record number of its devices. The company filed a Form 6-K
• EDAP TMS S.A. Files Form 6-K — May 16, 2024 Risk: low
  EDAP TMS S.A. filed a Form 6-K on May 16, 2024, to report its financial information. The filing indicates the company is a foreign private issuer and is submitt
• EDAP TMS SA Reports Record Q4 Revenue — Mar 27, 2024 Risk: medium
  EDAP TMS SA reported record fourth quarter 2023 total revenue of EUR 19.6 million ($21.3 million USD), a 24.8% increase over Q4 2022. The company also achieved
• EDAP TMS SA Announces FDA Breakthrough — Mar 4, 2024 Risk: low
  EDAP TMS S.A. announced on March 4, 2024, a significant breakthrough with the FDA for its Focal One device, marking a major step in prostate cancer treatment. T
• EDAP TMS Appoints Ken Mobeck CFO, Francois Dietsch CAO — Jan 2, 2024
  EDAP TMS SA, a global leader in robotic energy-based therapies, announced on January 2, 2024, the appointment of Ken Mobeck as its new Global Chief Financial Of

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX